Compare BridgeBio Pharma Inc (BBIO) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Zillow Group Inc Class A — how do they compare? BridgeBio Pharma Inc trades at $82.33 (market cap $16.46B), while Zillow Group Inc Class A trades at $33.63 (market cap $7.28B). The key difference: BridgeBio Pharma Inc is far larger — about 2.3× Zillow Group Inc Class A's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Zillow Group Inc Class A nearer its low. Which is the better fit depends on your goals.
| BBIO | ZG | |
|---|---|---|
Market Cap | $16.46B | $7.28B |
Sector | Health | Media |
52-Week High | $90.17 | $86.76 |
52-Week Low | $44.81 | $29.14 |
Enterprise Value | $18.02B | $6.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Zillow Group (ZG) trades at $31.94, down 0.19% with a bearish technical signal. The company shows improving fundamentals with revenue growth to $2.58B in 2025 and a return to profitability with $23M net income. Analyst consensus remains positive with a $57.80 price target, though recent securities class action lawsuits create near-term uncertainty. Technical indicators show the stock trading near support at $31 with resistance at $33.
ZG presents a mixed outlook with strong analyst support but significant legal overhangs. The company's turnaround to profitability and 51% buy rating suggest upside potential, but ongoing litigation regarding anticompetitive practices with Redfin poses substantial risk. Investors should weigh improving fundamentals against regulatory and legal challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
